These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30374010)

  • 1. [Endocrine therapy for prostate cancer.].
    Nagaya N; Horie S
    Clin Calcium; 2018; 28(11):1527-1533. PubMed ID: 30374010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
    Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
    Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
    J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
    Hauke R
    Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A; Dalla Volta A
    Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F; Buzzatti G; Rubagotti A; Boccardo F
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding heterogeneity of treatment effect in prostate cancer.
    Aly A; Mullins CD; Hussain A
    Curr Opin Oncol; 2015 May; 27(3):209-16. PubMed ID: 25689354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
    Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S
    J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Aggarwal RR; Ryan CJ; Chan JM
    Urol Oncol; 2013 Jul; 31(5):522-30. PubMed ID: 21658978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic treatment of advanced prostate cancer].
    Kretschmer A; Todenhöfer T
    Urologe A; 2020 Dec; 59(12):1565-1576. PubMed ID: 33201295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
    Hu YH; Guo JC; Zhang M
    Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration-Resistant Prostate Cancer: An Algorithmic Approach.
    Stratton K; Cookson M
    Urol Clin North Am; 2017 Nov; 44(4):647-655. PubMed ID: 29107280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.